147 related articles for article (PubMed ID: 9334899)
21. The conformational switch in muscarinic acetylcholine receptors.
Hulme EC; Lu ZL; Bee M; Curtis CA; Saldanha J
Life Sci; 2001 Apr; 68(22-23):2495-500. PubMed ID: 11392618
[TBL] [Abstract][Full Text] [Related]
22. Alanine scanning mutagenesis of conserved arginine/lysine-arginine/lysine-X-X-arginine/lysine G protein-activating motifs on m1 muscarinic acetylcholine receptors.
Lee NH; Geoghagen NS; Cheng E; Cline RT; Fraser CM
Mol Pharmacol; 1996 Jul; 50(1):140-8. PubMed ID: 8700106
[TBL] [Abstract][Full Text] [Related]
23. Molecular probes for muscarinic receptors: functionalized congeners of selective muscarinic antagonists.
Jacobson KA; Fischer B; van Rhee AM
Life Sci; 1995; 56(11-12):823-30. PubMed ID: 10188781
[TBL] [Abstract][Full Text] [Related]
24. Snake toxins that bind specifically to individual subtypes of muscarinic receptors.
Potter LT
Life Sci; 2001 Apr; 68(22-23):2541-7. PubMed ID: 11392624
[TBL] [Abstract][Full Text] [Related]
25. Discovery of a highly potent, functionally-selective muscarinic M1 agonist, WAY-132983 using rational drug design and receptor modelling.
Sabb AL; Husbands GM; Tokolics J; Stein RP; Tasse RP; Boast CA; Moyer JA; Abou-Gharbia M
Bioorg Med Chem Lett; 1999 Jul; 9(14):1895-900. PubMed ID: 10450949
[TBL] [Abstract][Full Text] [Related]
26. Molecular dynamics simulations of m3-muscarinic receptor activation and QSAR analysis.
Fanelli F; Menziani MC; De Benedetti PG
Bioorg Med Chem; 1995 Nov; 3(11):1465-77. PubMed ID: 8634826
[TBL] [Abstract][Full Text] [Related]
27. Binding-site modeling of the muscarinic m1 receptor: a combination of homology-based and indirect approaches.
Nordvall G; Hacksell U
J Med Chem; 1993 Apr; 36(8):967-76. PubMed ID: 8478909
[TBL] [Abstract][Full Text] [Related]
28. A model of the human M2 muscarinic acetylcholine receptor.
Jöhren K; Höltje HD
J Comput Aided Mol Des; 2002 Nov; 16(11):795-801. PubMed ID: 12825791
[TBL] [Abstract][Full Text] [Related]
29. Role of two highly conserved tyrosine residues in the m1 muscarinic receptor second transmembrane domain in ligand binding and receptor function.
Lee SY; Zhu SZ; el-Fakahany EE
Recept Signal Transduct; 1996; 6(1):43-52. PubMed ID: 8933621
[TBL] [Abstract][Full Text] [Related]
30. Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore.
Axe FU; Bembenek SD; Szalma S
J Mol Graph Model; 2006 May; 24(6):456-64. PubMed ID: 16386444
[TBL] [Abstract][Full Text] [Related]
31. Anti-muscarinic toxins from Dendroaspis angusticeps.
Liang JS; Carsi-Gabrenas J; Krajewski JL; McCafferty JM; Purkerson SL; Santiago MP; Strauss WL; Valentine HH; Potter LT
Toxicon; 1996; 34(11-12):1257-67. PubMed ID: 9027981
[TBL] [Abstract][Full Text] [Related]
32. Transmembrane domains 4 and 7 of the M(1) muscarinic acetylcholine receptor are critical for ligand binding and the receptor activation switch.
Lu ZL; Saldanha JW; Hulme EC
J Biol Chem; 2001 Sep; 276(36):34098-104. PubMed ID: 11441014
[TBL] [Abstract][Full Text] [Related]
33. Allosteric effects of four stereoisomers of a fused indole ring system with 3H-N-methylscopolamine and acetylcholine at M1-M4 muscarinic receptors.
Lazareno S; Birdsall B; Fukazawa T; Gharagozloo P; Hashimoto T; Kuwano H; Popham A; Sugimoto M; Birdsall NJ
Life Sci; 1999; 64(6-7):519-26. PubMed ID: 10069518
[TBL] [Abstract][Full Text] [Related]
34. Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.
Bromidge SM; Brown F; Cassidy F; Clark MS; Dabbs S; Hadley MS; Hawkins J; Loudon JM; Naylor CB; Orlek BS; Riley GJ
J Med Chem; 1997 Dec; 40(26):4265-80. PubMed ID: 9435896
[TBL] [Abstract][Full Text] [Related]
35. Muscarinic toxin 7 selectivity is dictated by extracellular receptor loops.
Kukkonen A; Peräkylä M; Akerman KE; Näsman J
J Biol Chem; 2004 Dec; 279(49):50923-9. PubMed ID: 15452105
[TBL] [Abstract][Full Text] [Related]
36. Muscarinic acetylcholine receptors: structural basis of ligand binding and G protein coupling.
Wess J; Blin N; Mutschler E; Blüml K
Life Sci; 1995; 56(11-12):915-22. PubMed ID: 10188793
[TBL] [Abstract][Full Text] [Related]
37. Pentatomic cyclic agonists and muscarinic receptors: a 20 years review.
Angeli P
Farmaco; 1995 Sep; 50(9):565-77. PubMed ID: 7495467
[TBL] [Abstract][Full Text] [Related]
38. 5-HT3 antagonists derived from aminopyridazine-type muscarinic M1 agonists.
Rival Y; Hoffmann R; Didier B; Rybaltchenko V; Bourguignon JJ; Wermuth CG
J Med Chem; 1998 Jan; 41(3):311-7. PubMed ID: 9464362
[TBL] [Abstract][Full Text] [Related]
39. Synthesis of novel and functionally selective non-competitive muscarinic antagonists as chemical probes.
Boulos JF; Jakubik J; Boulos JM; Randakova A; Momirov J
Chem Biol Drug Des; 2018 Jan; 91(1):93-104. PubMed ID: 28646631
[TBL] [Abstract][Full Text] [Related]
40. The M1 muscarinic receptor allosteric agonists AC-42 and 1-[1'-(2-methylbenzyl)-1,4'-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site.
Jacobson MA; Kreatsoulas C; Pascarella DM; O'Brien JA; Sur C
Mol Pharmacol; 2010 Oct; 78(4):648-57. PubMed ID: 20660086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
